CXCR4 Antibody | 1009

CXCR4 Antibody | 1009 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: Predicted species reactivity based on immunogen sequence: Bovine: (86%), Pig: (71%)

Immunogen: Anti-CXCR4 antibody (1009) was raised against a peptide corresponding to 14 amino acids near the amino terminus of human CXCR4 isoform b.
The immunogen is located within the first 50 amino acids of CXCR4.

Research Area: Chemokines & Cytokines, Stem Cell, Infectious Disease

Tested Application: E, WB, ICC, IP, IF, Flow, IHC-P

Application: WB: 1 - 2 μg/mL; IP/ ICC: 2 μg/mL; IHC-P: 5 μg/mL; IF: 20 μg/mL; Flow Cyt: 0.1 μg/mL.
Antibody validated: Western Blot in human, mouse, and rat samples; Immunohistochemistry, Immunocytochemistry and Immunofluorescence in human samples; Flow Cytometry in human and mouse samples. All other applications and species not yet tested.

Specificiy: CXCR4 Antibody is predicted to not cross-react with other CXCR familiy members.

Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate

Positive Control 2: Cat. No. 1202 - A431 Cell Lysate

Positive Control 3: Cat. No. 1210 - 293 Cell Lysate

Positive Control 4: Cat. No. 1211 – HepG2 Cell Lysate

Positive Control 5: Cat. No. 1282 – NIH/3T3 Cell Lysate

Positive Control 6: Cat. No. 1471 – Rat thymus Lysate

Molecular Weight: Predicted: 40 kDa
Observed: 44 kDa (Post-modification: 2 N-linked glycosylation)

Validation:

Independent Antibody Validation (Figure 2) shows similar CXCR4 expression profile in both human and mouse cell lines detected by two independent anti-CXCR4 antibodies that recognize different epitopes, 1009 against N-terminus ectodomain and 1012 against the second extracellular loop.  CXCR4 proteins are detected in most of the cell lines, but not in THP-1 cells by the two independent antibodies.  Additionally, Figure 2 shows the mouse CXCR4 protein in NIH/3T3 and C2C12 cell lines migrates slightly slower than human isoform b detected by both CXCR4 antibodies (1009 and 1012), which is well correlated with their calculated molecular masses (40.4 kDa vs 39.7 kDa). 

siRNA knockdown validation (Figure 3): Anti-CXCR4 antibody (1009) specificity was further verified by CXCR4 specific siRNA knockdown. CXCR4 signal in HeLa cells transfected with CXCR4 siRNAs was weaker in comparison with that in HeLa cells transfected with control siRNAs.

Animal Species Reactivity (Figure 4): Anti-CXCR4 antibodies (1009 and 1012) can detect the expression of CXCR4 protein in rat thymus, but not in rat brain and rat heart.

Recombinant Protein Test (Figure 5) shows that anti-CXCR4 antibody (1009) detects partial recombinant CXCR4 protein that contains the amino acids of 1009 antigenic peptide.  A band with same size can be observed in coomassie blue staining.

Isoform: Human CXCR4 has four isoforms, including isoform a (356aa, 40.2kD), isoform b (352aa, 39.7kD), isoform c (423aa, 47.6kD), and isoform d (385aa, 43.4kD). This antibody detects human isoform b only, but not other human isoforms. Mouse CXCR4 has two isoforms, including isoform 1 (359aa, 40.4kD) and isoform 2 (357aa, 40.2kD). Rat CXCR4 has only one isoform identified so far (349aa, 39.4kD).

Purification: CXCR4 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CXCR4 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CXCR4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CXCR4 Antibody: FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LESTR, NPY3R, NPYRL, HSY3RR, NPYY3R, D2S201E

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CXCR4, a G-protein coupled receptor (GPCR) with seven transmembrane domains, is a CXC chemokine receptor specific for stromal-derived-factor-1 (SDF-1 or CXCL12). CXCR4 was initially discovered as one of the co-receptors for HIV entry into CD4+ T cells (1). Blocking CXCR4 could be potentially used as novel therapeutics for HIV treatment.

CXCR4 signaling plays an important role in the migration, proliferation and quiescence of hematopoietic stem cell and their retention within the bone marrow, where it has high levels of SDF-1/CXCL12(2). It has been demonstrated that CXCR4 signaling mediates CD20 up-regulation on B cells (3).

CXCR4 is highly expressed in more than 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer, while there is very less or no expression of CXCR4 in healthy tissues. CXCR4 expression in cancer cells has been reported to be associated with tumor survival, growth and metastasis in tissues with high levels of SDF-1/CXCL12, such as lungs, liver and bone marrow (4,5).

CXCR4 has been shown to regulate neuronal migration, cell positioning and axon wiring (6,7). CXCR4 mutant mice displayed aberrant neuronal distribution, which implicates the role in neuronal disorders such as epilepsy. CXCR4 is also involved in WHIM syndrome (8). WHIM mutations in CXCR4 were recently found in patients with Waldenstrom's macroglobulinemia, and these mutations are correlated to clinical resistance to ibrutinib (9,10).